OM
CLSD

Opaleye Management’s Clearside Biomedical CLSD Stock Holding History

Opaleye Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18,000
Closed -$2.41M – 45
2016
Q4 		$2.41M Buy
+18,000
New +$4.52M 1.42% 24

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Opaleye Management's CLSD Position: Q1 2017 in Review

Opaleye Management sold out of Clearside Biomedical (CLSD) in Q1 2017, closing a stake of 18,000 shares — an estimated $2.41M sold.

Opaleye Management first reported a position in CLSD in Q4 2016 and held it in 1 quarter. The position peaked at $2.41M in Q4 2016. 59 funds tracked by Wall St. Rank hold CLSD as of Q1 2017.

  • Opaleye Management reported no remaining Clearside Biomedical position as of Q1 2017 after selling out during the quarter.
  • Opaleye Management sold 18,000 Clearside Biomedical shares in Q1 2017, an estimated $2.41M.
  • Opaleye Management first reported a position in Clearside Biomedical in Q4 2016 and held it in 1 quarter.
  • Opaleye Management's Clearside Biomedical position peaked at $2.41M in Q4 2016.
  • 59 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2017.

Based on Opaleye Management's 13F filing for Q1 2017, filed 15 May 2017.